Postdoctoral Fellow

Neelam  Mukherjee

Postdoctoral Fellow


Mentor:  Robert Svatek

Phone:  2103232370


I am a postdoctoral fellow with research interest in translational cancer biology and immune therapy. I have more than 7 years of molecular and cancer biology experience. As a Postdoctoral Fellow focusing on cancer immunology, I am specifically interested in the research for development of novel immunotherapies in the field of bladder oncology.


2008 BSc (Microbiology) University of Calcutta
2010 MSc (Microbiology) University of Calcutta
2015 PhD (Cellular and Structural Biology) UT Health San Antonio


Immunology, Immune Therapy, Bladder Oncology


2017 John Quale Fellow (BCAN)
2018 AACR Scholar-in-Training
2018 AAI Trainee Abstract Award
2019 Postdoctoral Fellowship Award, CPRIT-funded institutional Research Training
2019 Jackson Travel Schoarship Jackson Laboratories
2019 Young Investigator Award, Bladder Cancer Advocacy Network (BCAN)
2019 Poster Award (1st Place), 7th Annual San Antonio Postdoctoral Research Forum

Professional Memberships

2015-Present The American Association of Immunologists (AAI)
2015-Present Bladder Cancer Advocacy Network (BCAN)
2012-Present American Association for Cancer Research (AACR)
2015-Present American Association of Indian Scientists for Cancer Research (AAISCR)


  1. Mukherjee N., Ghosh R, Kumar P. DNA methylation and flavonoids in genitourinary cancers. Curr Pharmacol Rep., 2015, 1(2):112-120, (PMCID: PMC4437245).
  2. Mukherjee N, Houston TJ, Cardenas E and Ghosh R. To be an ally or an adversary in bladder cancer: why the NF-κB story has not unfolded. Carcinogenesis, 2015, 36(3):299-306, (PMCID: PMC4425835).
  3. Mukherjee N, Cardenas E, Bedolla R and Ghosh R. SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer. Oncotarget, 2017, 28;8(9):15114-15125, (PMCID: PMC5362471).
  4. Mukherjee N, Ji N, Hurez V, Curiel T, Montgomery M, Braun A, Nicolas M, Aguilera M, Kaushik D, Liu Q, Ruan J, Kendrick K and Svatek RS. Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer. Oncotarget, 2018, 9(92):36492-36502, (PMCID: PMC6284861).
  5. Mukherjee N, Liu  Q, Chen C, Huang T, Gelfond J, Lotan Y, Wheeler K, Ji N, Svatek RS. High frequency of intratumoral natural killer cells predicts improved survival for patients with locally advanced bladder cancer. J. Urol, 2019 (Under review).
  6. Brock EB, Cornell JE, Mukherjee N, Oppenheimer JS, Svatek RS. Efficacy of Bacillus Calmette-Guerin strains for the treatment of non-muscle invasive bladder cancer: A systematic review and network meta-analysis. J Urol, 2017, 198(3):503-510, (PMCID: PMC6464123).
  7. Mukherjee N, Wheeler K, Svatek RS. Bacillus Calmette-Guérin (BCG) treatment of bladder cancer: a systematic review and commentary on recent publications. Curr Opin Urol, 2019, 29(3):181-188, (PMID:30762672).
  8. Ji N, Mukherjee N, Morales E, Tomasini M, Hurez V, Curiel T, Abate G, Hoft D, Zhao X, Gelfond J, Maiti S, Cooper L, Svatek RS.  Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. OncoImmunology, 2019, (In press).
  9. Mukherjee N, Svatek RS, Mansour AM. Role of immunotherapy in BCG-relapsing non-muscle invasive bladder cancer. Urol Oncol, 2017, 36(3):103-108, (PMCID: PMC6428193).
  10. Svatek RS, Ji N, Leon E, Mukherjee N, Kabra A, Hurez V, Nicolas M, Michalek J, Javors M, Wheeler K, Sharp D, Livi C, Shu Z, Henkes D, and Curiel T. Rapamycin prevents surgery-induced immune dysfunction in patients with bladder cancer. Cancer Immunol Res, 2018, 7(3):466-475, (PMID: 30563829).
  11. Mukherjee N and Svatek RS. Prognostic significance and implications for therapy of PD-1 in BCG-relapsing bladder cancer. Ann Surg Oncol, 2018, 25(9):2498-2499, (PMID: 29971674).